Epidemiology of constipation in Europe and Oceania: a systematic review

Peppas, George; Alexiou, Vangelis G.; Mourtzoukou, Eleni G.; Falagas, Matthew E.

doi:10.1186/1471-230x-8-5

Cited by 305 publications

(281 citation statements)

References 40 publications

(50 reference statements)

Supporting

Mentioning

230

Contrasting

Unclassified

Order By: Relevance

“…Systematic reviews found a predominance of women and elderly people with CC 2, 3 and reported prevalence rates of 17.1% and 15.3% in Europe and Oceania, respectively 2. In an online survey of 5155 Japanese, 28.4% respondents self‐reported constipation 4.…”

Section: Introductionmentioning

confidence: 99%

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial

Kumagai

Aoki

Sasaki

et al. 2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsElobixibat is a minimally absorbed ileal bile acid transporter inhibitor. This study aimed to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of elobixibat in Japanese patients with chronic constipation.MethodsThis study consisted of single‐dose and multiple‐dose tests with a dose‐escalating design. Sixty patients including females and males were randomized into five dose levels of elobixibat (2.5, 5, 10, 15 or 20 mg, n = 10 per level) and corresponding placebo (n = 2 per group). A crossover design was used to examine food effect in single‐dose test. Patients received test tablets once daily for 14 days in multiple‐dose test. We assessed pharmacokinetic‐dose proportionality, levels of serum high‐ and low‐density lipoprotein cholesterol and plasma 7α‐hydroxy‐4‐cholesten‐3‐one (C4), food effect and sex‐specific effect. Adverse events and bowel functions such as bowel movements, stool consistency and straining were also evaluated.ResultsFood consumption reduced systemic exposure by around 80% [e.g. least squares mean (ratio of breakfast/no breakfast) maximum plasma concentration: 0.2085 (90% confidence interval, 0.1371–0.3172) at 15 mg] while increased plasma C4 level (P < 0.001). In the multiple‐dose test, elobixibat reduced low‐density lipoprotein cholesterol and increased C4 whilst unaltering high‐density lipoprotein cholesterol level. The increased spontaneous bowel movement frequency was correlated with higher dosage and higher C4 level (R2 = 0.5929 at Week 2). Adverse events were mainly gastrointestinal symptoms, most of which were mild.ConclusionsElobixibat should be taken before breakfast. Once‐daily administration of elobixibat was found to be safe and tolerated up to 20 mg in female and male patients with chronic constipation.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial

Kumagai

Aoki

Sasaki

et al. 2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Dados da América do Norte mostraram uma variação entre 2% e 27% na prevalência dessa doença 4,5,6 , e nos países da Europa e Oceania entre 5% e 35% 7 . No Brasil, não existem dados publicados de prevalência na população geral, visto que os estudos encontrados na literatura foram todos realizados em subgrupos, como lactentes 8 , adolescentes 9,10 e mulheres na menopausa 11 .…”

Section: Introductionunclassified

Prevalência e fatores associados à constipação intestinal: um estudo de base populacional em Pelotas, Rio Grande do Sul, Brasil, 2007

2010

View full text Add to dashboard Cite

show abstract

“…Constipation is one of the most common gastrointestinal complaints in Europe, with estimates of prevalence ranging from 5 to 35 % of the general population depending on the definition criteria used (57) . Definitions generally encompass aspects of defecation frequency with or without measures of stool consistency (57) .…”

Section: Gastrointestinal Healthmentioning

confidence: 99%

Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health

Stephen

Champ

Cloran³

et al. 2017

Nutr. Res. Rev.

502

450

View full text Add to dashboard Cite

Research into the analysis, physical properties and health effects of dietary fibre has continued steadily over the last 40-50 years. From the knowledge gained, countries have developed guidelines for their populations on the optimal amount of fibre to be consumed each day. Food composition tables from many countries now contain values for the dietary fibre content of foods, and, from these, combined with dietary surveys, population intakes have been determined. The present review assessed the uniformity of the analytical methods used, health claims permitted, recommendations and intakes, particularly from national surveys across Europe and around the world. It also assessed current knowledge on health effects of dietary fibre and related the impact of different fibre types on health. The overall intent was to be able to provide more detailed guidance on the types of fibre which should be consumed for good health, rather than simply a total intake figure, the current situation. Analysis of data indicated a fair degree of uniformity in the definition of dietary fibre, the method used for analysis, the recommended amount to be consumed and a growing literature on effects on digestive health and disease risk. However, national dietary survey data showed that intakes do not reach recommendations and very few countries provide guidance on the types of fibre that are preferable to achieve recommended intakes. Research gaps were identified and ideas suggested to provide information for more detailed advice to the public about specific food sources that should be consumed to achieve health benefits.

show abstract

Epidemiology of constipation in Europe and Oceania: a systematic review

Abstract: Background: We aimed to review the literature regarding the epidemiology of constipation in Europe and Oceania and the associated prevalence/risk factors.

Cited by 305 publications

References 40 publications

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial

Prevalência e fatores associados à constipação intestinal: um estudo de base populacional em Pelotas, Rio Grande do Sul, Brasil, 2007

Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health

Contact Info

Product

Resources

About